Determinants of liver disease progression in children with chronic hepatitis C virus infection

Maria Pokorska-Śpiewak1, Barbara Kowalik-Mikołajewska, Małgorzata Aniszewska

  • 1Maria Pokorska-Śpiewak MD, PhD, Department of Children's Infectious Diseases, Medical University of Warsaw, Wolska 37, 01-201 Warsaw, Poland, tel. +48 22 33 55 250, fax +48 22 33 55 379,

Insights

Chronic hepatitis C in children often shows mild liver damage, regardless of infection route. Higher BMI and longer infection duration predict more severe fibrosis, while aminotransferase levels correlate with liver inflammation and scarring.

Area of Science:

  • Pediatric Hepatology
  • Viral Hepatitis Research
  • Clinical Gastroenterology

Background:

  • Chronic hepatitis C (HCV) affects children, with vertical and horizontal transmission routes.
  • Understanding liver disease progression in pediatric HCV is crucial for long-term outcomes.

Purpose of the Study:

  • To analyze histopathological features of liver disease in children with chronic HCV.
  • To identify determinants of liver disease progression, including necroinflammation and fibrosis.

Main Methods:

  • Histopathological evaluation using Knodell's modified system in 42 treatment-naïve children.
  • Linear regression analyses to identify predictors of necroinflammation and fibrosis.

Main Results:

  • Most children exhibited mild necroinflammation and fibrosis, irrespective of transmission mode.
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels correlated with necroinflammation and fibrosis.
  • Increased duration of infection and higher BMI z-score were independent predictors of more severe fibrosis.

Conclusions:

  • Pediatric chronic HCV generally presents with mild liver changes over time.
  • Fibrosis progression is time-dependent; vertically infected children may develop it earlier.
  • Aminotransferase levels, infection duration, and BMI are key factors influencing liver disease severity in pediatric HCV.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
256
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
333
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
29
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
731
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
335
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
322